Drug profile · INN
peginterferon beta-1a
PLEGRIDY
peginterferon beta-1a (PLEGRIDY) is a interferon alpha/beta receptor agonist. Associated with Biogen. Route of administration: injection. Current US regulatory status: approved.
Drug details — peginterferon beta-1a
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L03)
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
peginterferon beta-1a (PLEGRIDY) is a interferon alpha/beta receptor agonist. Associated with Biogen. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interferon alpha/beta receptor agonist
Primary target: Interferon alpha/beta receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is peginterferon beta-1a?
peginterferon beta-1a (PLEGRIDY) is a interferon alpha/beta receptor agonist. Associated with Biogen. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for peginterferon beta-1a?
PLEGRIDY is a marketed brand name for peginterferon beta-1a. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of peginterferon beta-1a?
peginterferon beta-1a has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.